EGFR
Les inhibiteurs du récepteur du facteur de croissance épidermique (EGFR) sont des composés qui bloquent la signalisation de l'EGFR, un récepteur souvent surexprimé dans divers cancers et qui joue un rôle crucial dans l'angiogenèse. Les inhibiteurs de l'EGFR sont utilisés pour prévenir la croissance tumorale et les métastases en perturbant les voies qui favorisent la formation de vaisseaux sanguins dans les tumeurs. Ces inhibiteurs sont largement utilisés dans la recherche et le traitement du cancer. Chez CymitQuimica, nous offrons une sélection diversifiée d'inhibiteurs de l'EGFR de haute qualité pour soutenir vos recherches en oncologie et angiogenèse.
572 produits trouvés pour "EGFR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tarlox-TKI
CAS :<p>Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.</p>Formule :C19H18BrClN6ODegré de pureté :97.03%Couleur et forme :SolidMasse moléculaire :461.74EGFR-IN-69
CAS :<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Formule :C31H37Cl2N7O3SCouleur et forme :SolidMasse moléculaire :658.64EGFR-IN-67
CAS :<p>EGFR-IN-67 (Compound 7d) is a potent inhibitor of EGFR with anticancer activity (IC 50 = 0.34 μM) [1].</p>Formule :C18H17N3SCouleur et forme :SolidMasse moléculaire :307.41EGFR-IN-54
CAS :<p>EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.</p>Formule :C17H14N4O4S3Couleur et forme :SolidMasse moléculaire :434.51EGFR-IN-21
CAS :<p>EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.</p>Formule :C36H44BrN10O2PCouleur et forme :SolidMasse moléculaire :759.68NSC81111
CAS :<p>NSC81111 shows anticaner effects which is a potent and orally active inhibitor of EGFR-TK (IC50 = 0.15 nM) [1].</p>Formule :C19H16O4Couleur et forme :SolidMasse moléculaire :308.33EGFR-IN-73
CAS :<p>EGFR-IN-73 (Compound 3f) effectively inhibits the prevalent EGFR mutation, EGFR Del19, exhibiting an IC50 value of 119 nM [1].</p>Formule :C19H17ClFN3O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :405.81Antiproliferative agent-34
CAS :<p>Antiproliferative Agent-34 (Compound A14), a multitarget kinase inhibitor, demonstrates IC50 values of 177 nM for EGFR L858R/T790M and 1567 nM for EGFR WT.</p>Formule :C27H27N7O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :529.55EGFR-IN-89
CAS :<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Formule :C26H31FN8O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :538.64AG-183
CAS :<p>(Z)-Tyrphostin A51, a Z-isomer of Lanoconazole A51, is a strong PTK inhibitor blocking [3 H]taurine release and tyrosyl phosphorylation.</p>Formule :C13H8N4O3Couleur et forme :Brown SolidMasse moléculaire :268.23EGFR-IN-16
CAS :<p>EGFR-IN-16 (AG473) is an inhibitor of EGFR in human A431 cells.</p>Formule :C16H11NO3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :265.26(E/Z)-AG490
CAS :<p>(E/Z)-AG490 is a racemic mix of (E)- and (Z)-isomers; it inhibits tyrosine kinase, EGFR, Stat-3, and JAK2/3.</p>Formule :C17H14N2O3Couleur et forme :SolidMasse moléculaire :294.3EGFR-IN-75
<p>EGFR-IN-75 inhibits EGFR WT/T790M; IC50s: 0.28/5.02 μM. It has anticancer and antioxidant effects.</p>Formule :C10H6N6S2Couleur et forme :SolidMasse moléculaire :274.32CGP52411
CAS :<p>CGP52411 is an orally active, and ATP-competitive inhibitor of EGFR (IC50: 0.3 μM).</p>Formule :C20H15N3O2Degré de pureté :99.78%Couleur et forme :SolidMasse moléculaire :329.35EGFR-IN-50
CAS :<p>EGFR-IN-50, a potent EGFR blocker, hinders L858R mutation; GI50: 8 nM for TEL-EGFR-L858R, 6.03 μM for T790M-L858R; curbs cancer cell growth.</p>Formule :C24H26BrN3O4S2Couleur et forme :SolidMasse moléculaire :564.51EGFR-IN-53
CAS :<p>EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].</p>Formule :C14H13N3O2SCouleur et forme :SolidMasse moléculaire :287.34EGFR-IN-28
CAS :<p>EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity .</p>Formule :C31H39BrN10O3SCouleur et forme :SolidMasse moléculaire :711.68NSC114126
CAS :<p>NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formule :C22H20O4Couleur et forme :SolidMasse moléculaire :348.39BAY 2476568
CAS :<p>BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).</p>Formule :C24H27FN4O4Couleur et forme :SolidMasse moléculaire :454.49LDC0496
CAS :<p>LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.</p>Formule :C32H35N5O3Couleur et forme :SolidMasse moléculaire :537.65Lavendustin C6
CAS :<p>Lavendustin C6 is a effective tyrosine kinase inhibitor.</p>Formule :C20H25NO5Couleur et forme :SolidMasse moléculaire :359.42PDZ1i
CAS :<p>PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.</p>Formule :C28H26N8O4Couleur et forme :SolidMasse moléculaire :538.56Nazartinib mesylate
CAS :<p>Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).</p>Formule :C27H35ClN6O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :591.12Tyrphostin AG 112
CAS :<p>Tyrphostin AG 112 is an inhibitor of EGFR phosphorylation.</p>Formule :C13H8N4ODegré de pureté :97.01%Couleur et forme :SolidMasse moléculaire :236.23DBPR112
CAS :<p>DBPR112: oral furanopyrimidine EGFR inhibitor; IC50: 15 nM (EGFRWT), 48 nM (L858R/T790M); blocks ATP site, strong antitumor effects.</p>Formule :C32H31N5O3Degré de pureté :99.25%Couleur et forme :SolidMasse moléculaire :533.62Epertinib
CAS :<p>Epertinib is a reversible and selective tyrosine kinase inhibitor of EGFR, HER2, and HER4 (IC50s: 1.48 nM, 7.15 nM, and 2.49 nM).</p>Formule :C30H27ClFN5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :560.02MS 39
CAS :<p>MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.</p>Formule :C55H71ClFN9O7SCouleur et forme :SolidMasse moléculaire :1056.72RTC-5
CAS :<p>RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties.</p>Formule :C24H22ClF3N2O3SDegré de pureté :98.14%Couleur et forme :SolidMasse moléculaire :510.96SDZ281-977
CAS :<p>SDZ 281-977 is a derivative of Lavendustin A which is the EGF receptor tyrosine kinase inhibitor.</p>Formule :C18H20O5Degré de pureté :99.64%Couleur et forme :SolidMasse moléculaire :316.35EGFR-IN-2
CAS :<p>EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.</p>Formule :C26H33N9O3SDegré de pureté :98.52% - 99.79%Couleur et forme :SolidMasse moléculaire :551.66Gefitinib N-oxide
CAS :<p>Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.</p>Formule :C22H24ClFN4O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :462.9Nimotuzumab
CAS :<p>Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).</p>Degré de pureté :95.00% - 98.5% (SDS-PAGE); 96.4% (SEC-HPLC)Couleur et forme :LiquidEGFR-IN-5
CAS :<p>EGFR-IN-5 inhibits EGFR & mutants; IC50: EGFR 10.4nM, L858R 1.1nM, L858R/T790M 34nM, L858R/T790M/C797S 7.2nM.</p>Formule :C31H38FN9ODegré de pureté :98.17%Couleur et forme :SolidMasse moléculaire :571.69BKI-1369
CAS :<p>BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).</p>Formule :C23H27N7OCouleur et forme :SolidMasse moléculaire :417.51EGFR-IN-68
CAS :<p>EGFR-IN-68, an EGFR inhibitor, has an IC50 of 0.33 μM and shows significant anticancer effects.</p>Formule :C24H22N2OCouleur et forme :SolidMasse moléculaire :354.44JBJ-04-125-02
CAS :<p>JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.</p>Formule :C29H26FN5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :543.61EGFR mutant-IN-2
CAS :<p>EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].</p>Formule :C27H27F3N6O2SCouleur et forme :SolidMasse moléculaire :556.6Mutated EGFR-IN-2
CAS :<p>Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR.</p>Formule :C29H35FN8O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :562.64GW 583340 dihydrochloride
CAS :<p>GW 583340 dihydrochloride is a potent and orally available dual EGFR/ErbB2 inhibitor and inhibits 80% of tumor growth in a mouse xenograft mode.</p>Formule :C28H27Cl3FN5O3S2Degré de pureté :98.80%Couleur et forme :SolidMasse moléculaire :671.03EGFR-IN-64
CAS :<p>EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.</p>Formule :C20H21N3O3Couleur et forme :SolidMasse moléculaire :351.4JNJ28871063 hydrochloride
CAS :<p>ErbB receptor family inhibitor</p>Formule :C24H28Cl2N6O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :519.42Mutated EGFR-IN-3
CAS :<p>Mutated EGFR-IN-3: ATP-competitive, selective dibenzodiazepinone inhibitor for EGFR mutations, IC50 12-13 nM.</p>Formule :C31H29FN4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :508.59EMI48
CAS :<p>EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].</p>Formule :C21H20N2O3Couleur et forme :SolidMasse moléculaire :348.4EGFR-IN-39
CAS :<p>EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.</p>Formule :C24H25ClN6O3Couleur et forme :SolidMasse moléculaire :480.95Selatinib
CAS :<p>Selatinib is an orally active and potent dual inhibitor of EGFR and ErbB2 with anticancer activity that inhibits the growth of NCI-N87 tumor cells.</p>Formule :C29H26ClFN4O3SDegré de pureté :98.00%Couleur et forme :SolidMasse moléculaire :565.06EMI56
CAS :<p>EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].</p>Formule :C21H20N2O3Couleur et forme :SolidMasse moléculaire :348.4EGFR-IN-55
CAS :<p>"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."</p>Formule :C25H25Cl2N7O2Couleur et forme :SolidMasse moléculaire :526.42EGFR-IN-49
CAS :<p>EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.</p>Formule :C22H15N5O2SCouleur et forme :SolidMasse moléculaire :413.45EGFR-IN-31
CAS :<p>EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)</p>Formule :C32H36FN7O2Couleur et forme :SolidMasse moléculaire :569.67EGFR/HER2-IN-3
CAS :<p>EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.</p>Formule :C26H23N5O3Couleur et forme :SolidMasse moléculaire :453.49
